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The aim of the present study is to augment the prognostic power of breast cancer grading by elaboration of quantitative
histopathological methods. We focus on the recently introduced morphometrical grading system in which the three grading
sub-features of the WHO grading system are evaluated with the help of computerised nuclear morphometry, and quantitative
methods for assessing mitotic activity and tubular differentiation. The prognostic value of the morphometrical grading system is
now conﬁrmed in a material of 159 cases of invasive ductal breast cancer. In the current material the morphometrical grading
system very efﬁciently predicted the prognosis of breast cancer by dividing the patients into favourable (grade I), intermediate
(grade II), and unfavourable (grade III) outcome (P50.0001). The morphometrical grading system was especially efﬁcient in
identifying patients with the most unfavourable outcome. In our material the morphometrical grade III was associated with a
5.4-fold risk of breast cancer death. In light of the present results, the morphometrical grading can be applied to clinical use as
an aid in treatment decisions of patients with invasive ductal breast cancer.
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Histological malignancy grading of invasive ductal breast cancer
provides valuable information of the outcome of the patient (Parl
and Dupont 1982, Davis et al, 1986, Contesso et al, 1987, 1989;
Henson, 1988; Elston and Ellis, 1991; Simpson and Page, 1994;
Roberti et al, 1997; Page et al, 1998). Standardised applications
of the grading system have led to still higher accuracy in predicting
the outcome of breast cancer (Theissig et al, 1990; Royal College of
Pathologists Working Group, 1991; Elston and Ellis, 1991; Simpson
and Page, 1994). According to the Nottingham Breast Cancer
Study (Elston et al, 1982; Elston and Ellis, 1991) among grade
III tumours half of the patients will die of the disease within 5
years from the diagnosis. Instead, practically every patient with a
tumour of grade I is alive at 5 years of follow-up.
Since medical literature shows convincing evidence of the bene-
ﬁts of standardised methods in histological malignancy grading we
have set out to intensify the grading of invasive ductal breast
cancer by elaboration of quantitative morphometrical methods.
For the ﬁrst, we have introduced quantitative and computer-
assisted histopathological measurement methods by which the
extent of the three grading sub-features – nuclear pleomorphism,
mitotic activity and tubular differentiation – can be expressed in
numerical terms (Haapasalo et al, 1989; Kronqvist et al, 1995,
1997, 1999; Collan et al, 1996; Kuopio and Collan, 1996). Secondly,
on basis of follow-up information of a patient material we have
determined quantitative thresholds (Kronqvist et al, 1998a,b,
2000) for allocating each of the grading sub-features into scores
1, 2, and 3 (Patey and Scarff, 1928; Bloom and Richardson,
1957; WHO, 1981). The purpose of the present study is to examine
the prognostic value of the combined morphometrical grading
criteria in invasive ductal breast cancer.
MATERIALS AND METHODS
Patient material
The study comprises a total of 159 patients diagnosed and treated
with primary invasive ductal breast cancer at Turku University
Hospital during the years 1988–1991 (Table 1). The material origi-
nates from a period when mammographic screening was already
systematically practised in South Western Finland (Klemi et al,
1992, 1997). Complete follow-up histories and perioperative speci-
mens were available from the primary tumours of each case. All
patients were treated with radical or modiﬁed radical mastectomy
and axillary evacuation. Preoperative adjuvant treatment was not
administered, but 29% of the patients were treated with postopera-
tive anti-oestrogen medication or cytostatic drugs. In Turku
University Hospital district the indications for treatment with
anti-oestrogens and cytostatic drugs changed at the turn of the
decade. In the end of the 1980s, anti-oestrogens (tamoxifen) or
cytostatic drugs were given to patients with a T4 stage disease.
The same treatment was also given to patients detected with histo-
logically veriﬁed metastasis in four or more axillary lymph nodes
or in one or more apical lymph node. In the 1990’s, in turn, adju-
vant medication was given in all cases of histologically veriﬁed
spread to axillary lymph nodes.
For detailed statistical analysis the material was stratiﬁed into
prognostic subgroups. We used the age of 52 years at the time
of diagnosis as a criteria for allocating the material into premeno-
pausal and postmenopausal patient groups. This division was based
on the reported average menopausal age in Finnish population
(Saarikoski, 1986). Axillary lymph node status and tumour size
were also used to divide the patients into prognostic subgroups.
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nation of the axillary fat pad. Tumour size as expressed in
millimetres of the largest tumour diameter was obtained from
peroperative measurement by the surgeon, or in cases of non-palp-
able tumours, from the histological section. We used tumour
diameter 3 cm as the cut-point for allocating the patients into
prognostic subgroups. In the present material tumour size 3 cm
was shown to be the most efﬁcient cut-point for prognostic strati-
ﬁcation (P50.0003).
The causes of death were based on autopsy reports, death certi-
ﬁcates, and patient ﬁles. Breast cancer related survival rate was
71.3% as determined at 5 years of follow-up by excluding patients
dead of causes other than breast cancer.
Tissue processing
The tissue material prepared for morphometrical examinations was
ﬁxed in buffered formalin (pH 7.0), and embedded in parafﬁn.
From a representative tissue block of each case one slide was
prepared for morphometrical analyses. The tissue block was
sectioned at 5 mm, and stained with haematoxylin and eosin. No
pre-frozen tissue material was used in the measurements.
Histological malignancy grading
Of all breast cancer cases in the present material two grades were
available: the traditional subjective grade and the recently intro-
duced morphometrical grade. The subjective grades (Bloom and
Richardson, 1957; WHO, 1981) were obtained from histology
reports given in association with the original breast cancer diagno-
sis. The morphometrical grades were based on quantitative
measurements of each of the grading sub-features and their numer-
ical thresholds (Kronqvist et al, 1997, 1998b, 1999).
Nuclear measurements for morphometrical grading Nuclear
morphometrical measurements were performed with the help of
a digitising interactive video overlay drawing system run by the
Prodit morphometry program (Prodit 3.1, Promis Inc., Almere,
The Netherlands) (Table 2). In addition to a standard light micro-
scope the system included a personal computer (Compaq Deskpro
386/20e, Compaq Computer Corporation, Houston, TX, USA), a
video camera (JVC TK-870U, JVC, Japan), a monitor screen
(MultiSync 3D Color Monitor, NEC, Japan), and a digitiser board
(PIP-512B video digitiser board, Matrox Electronic Systems,
Dorval, Quebec, Canada). The nuclear proﬁles were measured by
outlining their digitised images on the monitor screen with the
computer mouse. Measurements were performed with 640 objec-
tive magniﬁcation which when added to the 610 video ocular and
62 internal magniﬁcation resulted in an image magniﬁcation of
62500 on the monitor screen. To ensure validity of results the
morphometric instrument was carefully calibrated with a micro-
metre slide before each measurement session.
In each sample the measurement area was selected at the most
cellular, usually peripheral part of the tumour which was consid-
ered to represent the invasive border of the tumour. These areas
were marked with ink and were approximately 0.5 cm in diameter.
Areas of necrosis, tissue artefacts, in situ carcinoma, and inﬂamma-
tion were avoided. In each microscopical ﬁeld those malignant
epithelial cell nuclei with clearly identiﬁed nuclear borders were
selected. An average of 6–15 adjacent microscope ﬁelds were
screened with a total of 50 consecutive tumour cell nuclei
measured in each sample. The number of measured cells per
sample was obtained from a pilot study comparing the value of
different sampling rules in nuclear morphometry (Kronqvist et
al, 1995). The optimal sample size can be theoretically conﬁrmed
when the desirable precision level and the probability of reaching
that precision is deﬁned (Collan et al, 1987). In the present study
the measurement of one sample took approximately 10–
15 minutes. After measurement of one sample was completed the
program automatically calculated 11 morphometrical variables with
their basic statistics. Five of the variables gave information about
the size of the nucleus and the remaining six variables characterised
the shape of the measured nuclear proﬁles. Among the morphome-
trical features describing nuclear size and shape and their variation,
the thresholds determined for the shortest nuclear axis was asso-
ciated with the highest statistical signiﬁcances (Kronqvist et al,
1998a). The thresholds for the shortest nuclear axis (SNA) were
therefore chosen optimal in stratifying cases on basis of their nucle-
ar pleomorphism (Kronqvist et al, 1998) (Table 2).
Mitotic counts for morphometrical grading Mitotic activities
of each sample were assessed in the same measurement areas that
were applied for nuclear morphometry. Mitoses were counted from
10 consecutive ﬁelds (objective 640, ﬁeld diameter 450 mm). Iden-
tiﬁcation of a mitotic ﬁgure was based on the absence of the
nuclear membrane and observation of at least one separate chro-
mosome, usually seen as a small protuberance or a clear hairy
projection at the outline of the mitotic ﬁgure. Special consideration
was put on discrimination between mitotic ﬁgures and apoptotic
bodies (Baak et al, 1989). In case of doubtful histological interpre-
tation a mitosis was not registered. Two chromosome collections
originating from one cell division were registered as one mitosis
in distinction from the principle of Baak et al (1989).
The mitotic calculations were performed by two laboratory tech-
nicians specially trained for the task (Kuopio and Collan, 1996). In
each microscopic ﬁeld the mitotic count together with the obser-
vers’ assessment on the area fraction of malignant epithelium
was entered on a form. The resulting standardised mitotic activity
(SMI) expressed the number of mitoses per square millimetre of
malignant epithelium. Evaluation of one sample took in average
10–15 min. The grading thresholds for SMI were determined so
that they optimally stratiﬁed cases into prognostic groups on the
basis of their mitotic activity (Kronqvist et al, 1998b) (Table 2).
The special advantage of SMI is that it takes into account the
amount of connective tissue within the tumour. This is especially
signiﬁcant in tumours with small cell density where the few mitoses
of the malignant tissue are dispersed among the large amount of
connective tissue. SMI was originally introduced by Haapasalo et
al (1989) as volume corrected mitotic index (M/V index) but in
a later paper on request of a referee the name was changed to stan-
dardised mitotic index (Collan et al, 1996). In the meantime, the
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Table 1 Characteristics of the patient material of 159 cases of invasive
ductal breast cancer
Mean age at diagnosis (range) 59.4 years (32.6–97.6 years)
Menopausal status
No. of premenopausal patients
(452 years) 53 (33.3%)
No. of postmenopausal patients
(452 years) 106 (66.7%)
Axillary lymph node status
No. of positive patients 67 (42.1%)
No. of negative patients 92 (57.9%)
Mean tumour size (range)* 3.0 cm (0.7–15 cm)
Mean follow-up time (range) 5 years 9 months
(2 months–8 years 11 months)
Causes of death during follow-up
Breast cancer 36 (23%)
Other cancer 5 (3%)
Other 10 (6%)
*Tumour size was deﬁned as the maximum tumour diameter as measured peropera-
tively by the operating surgeon or, in cases of non-palpable disease, during the
histological examination by the pathologist.
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used in one article (Kujari et al, 1994). Also this change in termi-
nology was demanded by a referee.
Evaluation of tubular differentiation for morphometrical
grading In assessing the degree of tubular differentiation in
breast cancer samples special consideration was placed on histolo-
gical identiﬁcation of the malignant glands. A gland was deﬁned as
a tubular or alveolar structure comprising a group of cancer cells
with a deﬁnite lumen at the centre. The basal location of the cancer
cell nuclei in the neoplastic glandular epithelium, the so-called
nuclear polarisation, was an additional criterion. Special caution
was taken not to misinterpret artefactual clefts caused by tissue
processing, adipocytes or central necrosis in a group of cancer cells
for tubular structures. Luminal structures in cribriform intraductal
or inﬁltrative epithelium as well as benign ducts within malignant
tissue were excluded from the measurements.
Our quantitative method for determining the degree of tubular
differentiation has proven accurate, reliable, and practical in
comparison to other tested evaluation methods (Kronqvist et al,
1999). In this method tubular differentiation was assessed in the
whole tumour area (WHO, 1981; Elston and Ellis, 1991; Simpson
and Page, 1994) by determining the presence or absence of malig-
nant tubuli in each microscopical ﬁeld (625 magniﬁcation, ﬁeld
diameter 710 mm) (Kronqvist et al, 1999) (Table 2). If at least
one unambiguous malignant tubular structure was identiﬁed the
ﬁeld was registered as positive. The number of positive ﬁelds in
relation to the total number of ﬁelds in the sample was called
the fraction of ﬁelds showing malignant tubuli (FTD). The evalua-
tion of one sample took 15–20 min.
Threshold analyses for morphometrical grading
For each of the above described morphometrically determined
grading sub-features two numerical thresholds were determined
in order to give quantitative scores to each of the grading sub-
features. Threshold determinations were performed with the help
of Kaplan–Meier analysis (Cutler and Ederer, 1958) and tested
with the help of chi-squares and P values of log-rank tests so that
the cut-points showing the best curve separation, i.e. the highest
statistical signiﬁcance, were considered to best distinguish patients
with different outcome of disease (Kronqvist, 1998a; b). These cut-
points represented the optimal grade limits and were chosen as
thresholds for morphometrical grading (Table 2). Finally, we added
together the scores based on morphometrical measurements and
quantitative thresholds of the grading sub-features. The breast
cancer cases of the present material were allocated to the morpho-
metrical grades on the basis of the original guidelines of Bloom
and Richardson (1957) (Table 2).
Statistical analysis
Agreements between the traditional subjective, and morphometri-
cal grading systems were analysed with the help of kappa
coefﬁcients (Landis and Koch, 1977; Kraemer, 1980; Wulff,
1981; Silcocks, 1992). Kappa coefﬁcients were used to estimate
the relation of the observed agreement to the expected random
agreement of the grading systems. Grading efﬁciencies (GE)
(Galen and Gambino, 1975; Collan, 1989; Collan and Pesonen,
1989; Collan et al, 1992, Kujari et al, 1994) were used to estimate
consistencies with respect to the fraction of uniformly graded
cases. GE’s were determined from 363 tables that evaluate strati-
ﬁcation of the cases into three grades by the subjective and
morphometrical grading system.
The prognostic contributions of the two grading systems were
demonstrated with the help of Kaplan–Meier analysis (Cutler
and Ederer, 1958) by drawing survival curves on basis of breast
cancer survival in the patient material (SAS System for Windows
TM
release 8.01, SAS Institute, Cary, NC, USA). P-values of log-rank
test were used to test the statistical signiﬁcances of differences
between the curves. Univariate and multivariate analyses of Cox’s
regression were used to determine the prognostic efﬁciency of
the morphometrical grading system. We compared the prognostic
signiﬁcances of the morphometrical grading system, and of the
patients’ age at diagnosis, tumour size, and axillary lymph node
status. The associations of the different prognostic factors with
breast cancer recurrence or death were quantiﬁed with ratios indi-
cating relative risk (RR) and their 95% conﬁdence intervals (95%
CI) in univariate and multivariate analyses.
RESULTS
In the present material the mean measurement value for MSNA
was 5.8 mm (range 3.1–11.1 mm), for SMI 16.8 (range 0–83.9),
and for FTD 31.3% (range 0–96.6%). On this basis 43% of the
cases were allocated to morphometrical grade I, 40% to morpho-
metrical grade II, and 16% to morphometrical grade III. The
corresponding fractions for subjective grades I, II and III were
15, 54 and 31%, respectively.
In 45% of the cases the subjective and morphometrical grading
systems resulted in identical grades. In 11 (7%) samples we
observed a disagreement between two grades and in these cases
there was a disagreement of the subjective grade III and the
morphometrical grade I. GE and kappa were 0.711 and 0.170
(95% CI 0.060–0.279), respectively, indicating poor agreement
between the traditional subjective, and morphometrical grading
methods.
Figure 1 shows the survival curves of the morphometrical
grades. In the whole material the morphometrical grades were
associated with a high prognostic signiﬁcance (log rank test
P50.0001). In analysis of the patient subgroups the morphometri-
cal grade showed prognostic signiﬁcance among axillary lymph
node positive (P50.0005) cases, and separately among both
premenopausal (P50.0006) and postmenopausal patients
(P50.012).
Instead, the subjective grading system did not separate with
statistical signiﬁcance patients with different outcome of disease
in the whole material (Figure 2) or in prognostic subgroups
divided according to the patients’ age at diagnosis, tumour size,
and axillary lymph node status. In fact, in our material we
observed the discrepancy of the cases representing subjective grade
II showing a more favourable prognosis than those of subjective
grade I.
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Table 2 Morphometrical grading system of invasive ductal breast cancer.
Nuclear pleomorphism is evaluated with the help of the mean shortest nu-
clear axis (MSNA), mitotic activity is expressed as the standardised mitotic
index (SMI), and the degree of tubular differentiation is assessed as the
ﬁelds showing tubular differentiation (FTD). After determining the scores
for each of the grading subfeatures the tumours is allocated into the re-
spective grade according to the total of the scores
Morphometrical score
Sub-feature 1 2 3
MSNA (mm) 54.8 4.8–6.4 46.4
SMI (mitoses/mm
72) 417 17–32 432
FTD (%) 459 59–23 523
Morphometrical grade
I II III
Total of scores 3, 4 and 5 6 and 7 8 and 9
Morphometrical grading in breast cancer
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1275–1280Risk ratios (RR) of univariate analysis of Cox’s regression are
presented in Table 3. The RR’s of both morphometrical and
subjective grading systems were produced by comparing the survi-
val of patients associated with each grade. The RR’s can be
expected to give comparative estimates on the value of the different
prognostic features. In analysis of the whole material, morphome-
trical grades I and II vs III were associated with a 2.8-fold risk of
breast cancer death (P50.005). Morphometrical grade reliably
predicted the prognosis also among axillary lymph node positive
and negative patients, and premenopausal patients (RR’s ranging
from 5.1 to 1.2). Instead, the traditional subjective grades did
not predict patient outcome in our material with statistical signiﬁ-
cance.
The results of multivariate analysis (Table 4) show the relation
between the evaluated prognostic features using grade I as the
reference risk ratio. In our material the risk of breast cancer death
increased 3.4-fold when the morphometrical grade rose from grade
I to grade II (P50.01). Between grades I and III the risk of breast
cancer death increased 5.4-fold (P50.001). The highest risk ratios
of breast cancer death were observed among axillary lymph node
positive patients where morphometrical grade III was associated
with over 12-fold risk of breast cancer death as compared with
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Figure 1 The morphometrical grading system separated the patients
with tumours of grades I, II, and III with high statistical signiﬁcance
(P50.0001).
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Figure 2 Survival curves for the subjective grades I, II, and III did not stra-
tify the patients with different outcome of disease with statistical signiﬁ-
cance (P=0.275).
Table 4 Multivariate analyses performed in the material of 159 patients
on the morphometric grade, and the traditional subjective grade with tu-
mour size, axillary lymph node status, and menopausal status at the time
of diagnosis. The analysis is performed by using grade I as the reference.
In addition to the P values, risk ratios (RR) of breast cancer death with
95% conﬁdence intervals (95% CI) are shown
Morphometric grade
Group of patients Feature P RR 95% CI
All Grade I 0.004 1.0
Grade II 0.010 3.4 1.3–8.7
Grade III 0.001 5.4 2.0–14.8
Node 0.181 1.6 0.8–3.3
Menopausal status 0.677 1.0 0.9–1.0
Tumour size 0.023 2.3 1.1–4.6
Node 7 Grade I 0.096 1.0
Grade II 0.034 3.7 1.1–12.3
Grade III 0.577 1.7 0.3–10.0
Menopausal status 0.696 1.0 1.0–1.0
Tumour size 0.061 3.0 1.0–9.3
Node + Grade I 0.004 1.0
Grade II 0.061 4.4 0.9–20.4
Grade III 0.002 12.1 2.5–58.9
Menopausal status 0.405 1.0 1.0–1.0
Tumour size 0.067 2.4 0.9–6.0
Subjective grade
Group of patients Feature P RR 95% CI
All Grade I 0.262 1.0
Grade II 0.181 0.5 0.2–1.4
Grade III 0.722 0.8 0.3–2.4
Node 0.065 2.0 1.0–4.0
Menopausal status 0.973 1.0 1.0–1.0
Tumour size 0.005 2.9 1.4–6.0
Node 7 Grade I 0.139 1.0
Grade II 0.047 0.2 0.6–1.0
Grade III 0.266 0.4 0.1–2.1
Menopausal status 0.797 0.0 1.0–1.0
Tumour size 0.400 3.1 0.7–14.0
Node + Grade I 0.493 1.0
Grade II 0.974 1.0 0.2–5.0
Grade III 0.502 1.7 0.3–8.8
Menopausal status 0.974 1.0 1.0–1.0
Tumour size 0.034 2.8 1.1–7.1
Table 3 Univariate analysis of both the morphometrical and the tradi-
tional subjective grade performed in the whole material of 159 patients,
and in prognostic subgroups divided according to the patients’ axillary
lymph node status and age at the time of the diagnosis. In addition to
the P values, risk ratios (RR) of breast cancer death with 95% conﬁdence
intervals (95% CI) are shown
Morphological grade I vs II vs III
Group of patients P RR 95% CI
All 50.0001 2.4 1.6–3.8
Node 7 0.1093 1.7 0.9–3.4
Node + 0.0005 3.0 1.6–5.6
Premenopausal 0.0006 4.5 1.9–10.5
Postmenopausal 0.0187 1.9 1.1–3.2
Morphological grade I and II vs III
Group of patients P RR 95% CI
All 0.0043 2.8 1.4–5.7
Node 7 0.7810 1.2 0.3–5.5
Node + 0.0030 3.7 1.6–8.8
Premenopausal 0.0036 5.1 1.7–15.5
Postmenopausal 0.2262 1.8 0.7–5.0
Subjective grade I vs II vs III
Group of patients P RR 95% CI
All 0.3833 1.3 0.8–2.1
Node 7 0.9957 1.0 0.4–2.2
Node + 0.2229 1.5 0.8–3.0
Premenopausal 0.4683 1.4 0.5–4.0
Postmenopausal 0.5702 1.2 0.6–2.2
Abbreviations: All, all patients; Node 7, axillary lymph node negative patients; Node
+, axillary lymph node positive patients.
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grades produced statistically signiﬁcant risk ratios of breast cancer
death.
CONCLUSIONS
In the medical literature, there is abundant conﬁrmation on the prog-
nostic signiﬁcance of the histological grading of invasive breast cancer
(Davis et al, 1986; Contesso et al, 1987, 1989; Elston and Ellis, 1991;
Aaltomaa et al, 1991; Simpson and Page, 1994; Roberti, 1997; Page et
al, 1998). Grading has also been acknowledged to have additional
prognostic value in small (51 cm in diameter) and axillary lymph
node-negative tumours (Hopton et al, 1989; Stierer et al, 1992; Lee
et al, 1996). When comparing the different methods to evaluate the
prognosis of breast cancer, the predictive value of histological grading
has been found to exceed that of hormone receptor status, DNA
content, and c-erbB-2 or p5+3 expression (Fisher et al, 1988; Merkle
et al, 1993; MacGrogan et al, 1995; Quenel et al, 1995). Although the
bulk of information supports the prognostic correlations of breast
cancer grading, other opinions also exist (Calle et al, 1986; Masters
et al, 1987; Rosner and Lane, 1990; Johnson et al, 1992). The majority
of criticism regarding breast cancer grading has centred on the lack of
uniform methodology.
The morphometrical grading system is a method that applies
quantitative morphometrical measurements and numerical assess-
ment criteria for determining the degree of malignancy in
invasive ductal breast cancer. In the present study we have exam-
ined the prognostic power of this modiﬁed grading system in
predicting the outcome of 159 breast cancer patients. According
to the current results, the morphometrical grading system very efﬁ-
ciently predicts the prognosis of breast cancer by dividing the
patients into groups of favourable (grade I), intermediate (grade
II) and unfavourable (grade III) outcome (log rank test
P50.0001). Moreover, patients were reliably classiﬁed into the
different grades in prognostic subgroups divided on basis of axil-
lary lymph node status and menopausal status. The prognostic
signiﬁcance of the morphometrical grading system is enhanced
by the fact that the present analyses are based on follow-up infor-
mation of a recent patient material representative of the era of
mammographic screening and adjuvant treatment.
In this study we compared the prognostic value of the two grad-
ing methods according to the risk of breast cancer death associated
with them. The risk of breast cancer death associated with the
morphometrical grades in our material was 2.8 (P50.005). In
our material the morphometrical grade was especially efﬁcient in
determining patiens with the most unfavourable prognosis (grade
III) (RR’s varying between 1.2 to 5.1 in different prognostic
subgroups). In multivariate analysis the risk ratios of the morpho-
metrical grading system logically increased by each grade with
grade III being associated with a 5.4-fold risk of breast cancer death
(P50.001).
In survival analysis the prognostic value of the subjective grading
(Bloom and Richardson, 1957; WHO, 1981) was clearly inferior to
that of the morphometrical grading. The relatively short follow-up
time can partly explain why the traditional subjective grades did
not show prognostic signiﬁcance in our material. The traditional
subjective grades also differed decisively from the morphometrical
grades. Application of the morphometrical grading led the classiﬁ-
cation towards the less malignant end of the scale as compared
with the subjective grading. Moreover, the morphometrical grading
system can be considered especially beneﬁcial since it resulted in a
diminished amount of cases representing an intermediate and
consequently more uncertain outcome of disease (grade II).
Since breast cancer is known to be a heterogenous disease the
nominal category of the diagnosis alone does not provide the clin-
ician with sufﬁcient information for treatment decisions. Therefore
further classiﬁcation systems, such as histological grading, have
been developed. In light of the present results, the morphometrical
grading system can be applied to clinical use as an aid in treatment
decisions of patients with invasive ductal breast cancer. In addition
to predicting the prognosis, the system could be used for standar-
disation and training of grading performance, and in the audit
procedure of quality control.
The presented morphometrical grading system provides breast
cancer grading new, more exact and reproducible principles, methods
and criteria. In establishing new prognosticators, however, the clini-
cal applicability of the method has to be considered. In a routine
setting the morphometrical grading is obviously more laborious
and time consuming than the traditional subjective grading.
Morphometrical grading of one sample takes approximately
30 min which is considerably more than the time generally used in
subjective grading. However, this does not necessarily increase the
work load of the pathologist since the necessary morphometrical
measurements can be performed by adequately trained laboratory
personnel. The morphometrical grade can also be used in prognosti-
cation of certain patient subgroups, e.g. axillary lymph node positive
patients. The morphometrical grading system could also be useful in
standardising grading performance between laboratories, in training
during pathology specialisation, and in clinical quality control. Also,
the methods and criteria of the morphometrical grading system can
be applied to the subjective grading of breast cancer in order to inten-
sify the prognostic efﬁciency.
Development of a quantitative morphometrical grading system
will require continued efforts. In the next phase it will be necessary
to clarify the concomitant prognostic values of the grading features.
This is especially motivated since previous studies suggest that the
prognostic power of mitotic counts by far exceeds that of the other
prognostic features (Clayton, 1991; van Diest and Baak, 1991).
These ﬁndings could lead to development of a morphometric index
where each grading feature would be provided with a coefﬁcient
reﬂecting the weight of the feature in prognostication. Application
of artiﬁcial intelligence in the form of decision support systems
would also be an elegant solution for unequal prognostic values
(Ravdin and Clark, 1992; Ravdin et al, 1992). Finally, the results
give a scientiﬁc medical basis for production of a future automated
image analysis programme for morphometrical grading.
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